Please ensure Javascript is enabled for purposes of website accessibility

Why NewLink Genetics, Harmonic, and Innophos Holdings Slumped Today

By Dan Caplinger - Apr 5, 2017 at 4:56PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These stocks helped lead the market lower. Find out why.

Wednesday was an up-and-down day for the stock market, but major market benchmarks ended up on the short end of the stick and finished with losses of 0.2% to 0.5%. Throughout much of the day, investors seemed to be pleased with continuing signs of growth in the U.S. economy, pointing to the likelihood that a recession is still far away and that the bull market in stocks could continue indefinitely. Yet later in the afternoon, the release of the latest minutes from the Federal Open Market Committee meeting set a different tone. In addition, some stocks posted particularly poor showings, and NewLink Genetics (NLNK), Harmonic (HLIT 3.91%), and Innophos Holdings (IPHS) were among the worst performers on the day. Below, we'll look more closely at these stocks to tell you why they did so poorly.

NewLink disappoints with data

Shares of NewLink Genetics dropped 14% after the biopharmaceutical company released interim results from its phase 2 study of experimental melanoma treatment indoximod. NewLink said that objective response rates came in between 50% and 60% in the study of 60 patients, with disease control rates of 70% to 80%. Yet although Chief Medical Officer Nicholas Vehanian said that the data "further underscore the potential for indoximod in combination with other agents," characterizing the rates as "highly encouraging," investors seemed unimpressed and concerned that failing to produce even stronger performance might leave NewLink vulnerable to competition. With a long road ahead of it, NewLink will inevitably have ups and downs with future study results as the trials progress.

Layout of Harmonic cloud media processing platform.

Image source: Harmonic.

Harmonic fails to impress

Harmonic stock declined 8% despite the company having showcased new technology at an industry conference. The video delivery infrastructure specialist offered new software-based solutions that it believes could transform the future of media processing, allowing users to take full advantage of changes in media environments. In particular, Harmonic's over-the-top and cloud-based solutions will give customers the ability to release broadcast, live, and on-demand video offerings quickly and with high quality and low cost. Yet investors didn't appear convinced that the conference showcase would result in a faster road to success for Harmonic, whose stock still trades at a third less than what it did in early 2015.

Innophos' new strategic plan leaves investors wanting

Finally, shares of Innophos Holdings fell 8%. The specialty-ingredient specialist released its "Vision 2022" strategic plan today, which includes a five-year growth trajectory that it hopes to achieve through several key initiatives. In particular, Innophos believes it needs to strengthen its core business in its phosphate-based food, health, and industrial products while growing through acquisition. At the same time, strategic partnerships with customers, suppliers, and marketing and technology partners could help bolster Innophos' business, and the company expects to keep cutting costs to boost efficiency. Yet the company wasn't able to improve its guidance for 2017, which includes a 4% drop in expected sales and flat earnings from 2016 levels. Until these efforts bear fruit, Innophos could see continuing pressure to perform.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Harmonic Inc. Stock Quote
Harmonic Inc.
HLIT
$9.30 (3.91%) $0.35
NewLink Genetics Corporation Stock Quote
NewLink Genetics Corporation
NLNK
Innophos Holdings, Inc. Stock Quote
Innophos Holdings, Inc.
IPHS

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
349%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.